|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Brigham and Women's Hospital |
|---|---|
| Information provided by (Responsible Party): | Daniel Jay Pallin, MD, MPH, Brigham and Women's Hospital |
| ClinicalTrials.gov Identifier: | NCT00676130 |
Purpose
The primary aim of this study is to quantify the effectiveness of Bactrim as additional therapy for the treatment of uncomplicated cellulitis in adults, by comparing: standard therapy plus Bactrim, versus standard therapy plus placebo.
The primary hypothesis of this study is that, in light of increasing CA-MRSA prevalence, subjects treated with standard therapy plus Bactrim will have higher cure rates than those treated with standard therapy plus placebo.
| Condition | Intervention |
|---|---|
|
Cellulitis |
Drug: Cephalexin + Trimethoprim Sulfamethoxazole Drug: Cephalexin + Placebo |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator) Primary Purpose: Treatment |
| Official Title: | Randomized Trial of Trimethoprim-Sulfamethoxazole Versus Placebo Added to Standard Treatment of Uncomplicated Cellulitis in Emergency Department Patients |
| Estimated Enrollment: | 144 |
| Study Start Date: | May 2007 |
| Estimated Study Completion Date: | May 2012 |
| Estimated Primary Completion Date: | December 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Placebo Comparator: I |
Drug: Cephalexin + Placebo
Weight-based dosing in capsule or suspension form according to the following scale: 15-19 kg (33-42 lbs): Cephalexin 300 mg qid 20-24 kg (42-53 lbs): Cephalexin 400 mg qid 25-29 kg (53-64 lbs): Cephalexin 500 mg qid 29-60 kg (64-132 lbs): Cephalexin 500 mg qid 60-80 kg (132-176 lbs): Cephalexin 1000 mg tid > 80 kg (176 lbs): Cephalexin 1000 mg qid |
| Experimental: II |
Drug: Cephalexin + Trimethoprim Sulfamethoxazole
Weight-based dosing in capsule or suspension form according to the following scale: 15-19 kg (33-42 lbs): Trimethoprim-Sulfamethoxazole (Bactrim) 40/200 mg qid; Cephalexin 300 mg qid 20-24 kg (42-53 lbs): Trimethoprim-Sulfamethoxazole (Bactrim) 60/300 mg qid; Cephalexin 400 mg qid 25-29 kg (53-64 lbs): Trimethoprim-Sulfamethoxazole (Bactrim) 72/360 mg qid; Cephalexin 500 mg qid 29-60 kg (64-132 lbs): Trimethoprim-Sulfamethoxazole (Bactrim) 80/400 mg qid; Cephalexin 500 mg qid 60 kg (132 lbs): Trimethoprim Sulfamethoxazole (Bactrim) 80/400 mg qid; Cephalexin 500 mg qid 60-80 kg (132-176 lbs): Trimethoprim Sulfamethoxazole (Bactrim) 160/800 mg tid; Cephalexin 1000 mg tid > 80 kg (176 lbs): Trimethoprim Sulfamethoxazole (Bactrim) 160/800 mg qid; Cephalexin 1000 mg qid |
Eligibility| Ages Eligible for Study: | 12 Months and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria
Must have cellulitis as defined here:
Definition A (preferred definition):
Recent onset of soft tissue erythema, considered by the treating clinician to be bacterial in origin, and associated with signs of infection that include at least two of the following: pain, swelling, warmth, fever, lymphangitis, induration, or ulceration.
Definition B (ONLY for darkly-pigmented subjects who cannot use Definition A):
Recent onset of soft tissue color change, pain, or swelling, considered by the treating clinician to be bacterial in origin, and at least one of the following: warmth, fever, induration, or ulceration
Exclusion Criteria:
Contacts and Locations| United States, Massachusetts | |
| Brigham and Women's Hospital | |
| Boston, Massachusetts, United States, 02115 | |
| Massachusetts General Hospital | |
| Boston, Massachusetts, United States, 02114 | |
| Children's Hospital Boston | |
| Boston, Massachusetts, United States, 02115 | |
| Principal Investigator: | Daniel J. Pallin, MD, MPH | Brigham and Women's Hospital |
More Information
| Responsible Party: | Daniel Jay Pallin, MD, MPH, Associate Research Director, Department of Emergency Medicine, Brigham and Women's Hospital |
| ClinicalTrials.gov Identifier: | NCT00676130 History of Changes |
| Other Study ID Numbers: | 2007P000414, F8349839 |
| Study First Received: | December 28, 2007 |
| Last Updated: | December 27, 2011 |
| Health Authority: | United States: Institutional Review Board |
|
Cellulitis Bactrim Trimethoprim Sulfamethoxazole MRSA Methicillin-resistant Staphylococcus aureus |
|
Cellulitis Emergencies Skin Diseases, Infectious Infection Suppuration Connective Tissue Diseases Inflammation Pathologic Processes Disease Attributes Cephalexin Sulfamethoxazole Trimethoprim Trimethoprim-Sulfamethoxazole Combination |
Anti-Bacterial Agents Anti-Infective Agents Therapeutic Uses Pharmacologic Actions Anti-Infective Agents, Urinary Renal Agents Antimalarials Antiprotozoal Agents Antiparasitic Agents Folic Acid Antagonists Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |